These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38133187)

  • 21. DAXI (DaxibotulinumtoxinA) - An Innovative Approach for Frown Lines.
    Mussarat A; Mustafa MS; Azam ST; Nafees Uddin MM; Nasrullah RMU; Siddiq MA
    Int J Gen Med; 2023; 16():1267-1269. PubMed ID: 37065981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Upper Facial Lines With DaxibotulinumtoxinA for Injection: Results From an Open-Label Phase 2 Study.
    Dover JS; Humphrey SD; Lorenc ZP; Shamban A; Gross TM; Rubio RG; Vitarella D
    Dermatol Surg; 2023 Jan; 49(1):60-65. PubMed ID: 36533798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased patient comfort utilizing botulinum toxin type a reconstituted with preserved versus nonpreserved saline.
    Kwiat DM; Bersani TA; Bersani A
    Ophthalmic Plast Reconstr Surg; 2004 May; 20(3):186-9. PubMed ID: 15167724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AbobotulinumtoxinA (Dysport
    Field M; Splevins A; Picaut P; van der Schans M; Langenberg J; Noort D; Snyder D; Foster K
    Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bacteriostatic preserved saline for pain-free periocular injections: review.
    Hunt SV; Malhotra R
    Eye (Lond); 2022 Aug; 36(8):1546-1552. PubMed ID: 35017698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies on the dissociation of botulinum neurotoxin type A complexes.
    Eisele KH; Fink K; Vey M; Taylor HV
    Toxicon; 2011 Mar; 57(4):555-65. PubMed ID: 21195107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Questioning the need to use Botox within 4 hours of reconstitution: a study of fresh vs 2-week-old Botox.
    Yang GC; Chiu RJ; Gillman GS
    Arch Facial Plast Surg; 2008; 10(4):273-9. PubMed ID: 18645097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term stability of reconstituted incobotulinumtoxinA: how can we reduce costs of botulinum toxin therapy?
    Dressler D; Bigalke H
    J Neural Transm (Vienna); 2017 Oct; 124(10):1223-1225. PubMed ID: 28770389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sterility assessment of multiple use botulinum A exotoxin vials: a prospective simulation.
    Alam M; Yoo SS; Wrone DA; White LE; Kim JY
    J Am Acad Dermatol; 2006 Aug; 55(2):272-5. PubMed ID: 16844511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study.
    Allen SB; Goldenberg NA
    Dermatol Surg; 2012 Jun; 38(6):867-70. PubMed ID: 22268727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of fresh versus refrigerated botulinum toxin in the treatment of lateral periorbital rhytids.
    Hui JI; Lee WW
    Ophthalmic Plast Reconstr Surg; 2007; 23(6):433-8. PubMed ID: 18030112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use.
    Sloop RR; Cole BA; Escutin RO
    Neurology; 1997 Jan; 48(1):249-53. PubMed ID: 9008526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison and overview of currently available neurotoxins.
    Walker TJ; Dayan SH
    J Clin Aesthet Dermatol; 2014 Feb; 7(2):31-9. PubMed ID: 24587850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
    Wortzman MS; Pickett A
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S34-42. PubMed ID: 19945003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension.
    Lambert O; Bandilla D
    Drug Des Devel Ther; 2012; 6():235-44. PubMed ID: 23049244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of bacterial or fungal growth in vials of reconstituted botulinum toxin type A after storage.
    Osaki T; Osaki MH; Osaki TH; Sant'Anna AE; Yu MC; Hofling-Lima AL
    Aesthet Surg J; 2015 Feb; 35(2):189-93. PubMed ID: 25717119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 Study.
    Green JB; Mariwalla K; Coleman K; Ablon G; Weinkle SH; Gallagher CJ; Vitarella D; Rubio RG
    Dermatol Surg; 2021 Jan; 47(1):42-46. PubMed ID: 32773447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro stability of two formulations of recombinant activated factor VIIa reconstituted in inappropriate solvents or at inappropriate volumes.
    Petersson B; Schönwandt AB; Thornstfeldt P; Nedergaard H; Jensen MB; Thornstergaard PB; Norsell T; Bjerre J
    Clin Ther; 2008 May; 30(5):917-23. PubMed ID: 18555938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stability of Ribavirin for Inhalation Packaged in Syringes or Glass Vials when Stored Frozen, Refrigerated, and at Room Temperature.
    Larson B; Bushman LR; Casciano ML; Oldland AR; Kiser JJ; Kiser TH
    Int J Pharm Compd; 2016; 20(6):521-525. PubMed ID: 28339392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recovery from botulinum neurotoxin poisoning in vivo.
    Keller JE
    Neuroscience; 2006 May; 139(2):629-37. PubMed ID: 16490322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.